Shandong Pharmaceutical Glass invests $28m in structured deposit product

Shandong Pharmaceutical Glass Company Limited has invested RMB 28,000,000.00 with the Industrial and Commercial Bank of China Limited in a "Structured Deposit Product for Corporate Clients – Dedicated Account, Type C, Issue 429, 2025." This 92-day product is principal-protected with an estimated annualized yield of 0.80% to 1.80%, projected to generate between RMB 56,460.00 and RMB 127,040.00 in income.

This investment falls within the total authorized limit of RMB 800,000,000.00 for principal-protected wealth management products, approved by the 2024 annual general meeting. The company emphasizes that this use of funds aims to enhance efficiency and returns for shareholders without impacting the progress of its investment projects.

As of the announcement date, the company has utilized RMB 730,000,000.00 of non-public offering funds for wealth management products. The investment period for this particular product begins on December 11, 2025, and matures on March 13, 2026.